Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $12.00, for a total transaction of $19,620.00. Following the transaction, the insider directly owned 8,617 shares of the company’s stock, valued at approximately $103,404. This represents a 15.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Scott Bizily also recently made the following trade(s):

• On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.20, for a total transaction of $19,947.00.
• On Tuesday, June 23rd, Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00.

4D Molecular Therapeutics Trading Up 19.4%

NASDAQ FDMT traded up $2.36 during trading on Monday, hitting $14.55. The stock had a trading volume of 3,444,983 shares, compared to its average volume of 805,311. 4D Molecular Therapeutics, Inc. has a one year low of $5.97 and a one year high of $15.03. The stock has a 50 day simple moving average of $10.94 and a 200 day simple moving average of $9.89. The stock has a market capitalization of $760.67 million, a price-to-earnings ratio of -5.53 and a beta of 2.73. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. The business had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. Sell-side analysts predict that 4D Molecular Therapeutics, Inc. will post -3.88 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. Chardan Capital raised shares of 4D Molecular Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $32.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.62.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Persistent Asset Partners Ltd bought a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at about $1,936,000. Dimensional Fund Advisors LP increased its holdings in 4D Molecular Therapeutics by 77.3% during the first quarter. Dimensional Fund Advisors LP now owns 522,823 shares of the company’s stock valued at $4,863,000 after buying an additional 227,982 shares during the period. Exome Asset Management LLC bought a new position in 4D Molecular Therapeutics in the first quarter worth approximately $1,216,000. Evergreen Quality Fund GP Ltd. bought a new position in 4D Molecular Therapeutics in the fourth quarter worth approximately $7,136,000. Finally, Simplify Asset Management Inc. purchased a new stake in 4D Molecular Therapeutics during the first quarter worth $656,000. 99.27% of the stock is currently owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.